Potential use of glucocorticosteroids in CSF1R mutation carriers - current evidence and future directions.

Abstract excerpt

We recently found that glucocorticosteroids (GCs) have protective effects in CSF1R mutation carriers against developing symptomatic CSF1R-related leukoencephalopathy. Our findings were subsequently confirmed in a mouse model study. We have received many questions from patients, their families, patient organisations, and healthcare practitioners about the optimal type of GCs, the dose, the route of administration,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Leukoencephalopathies
• Share to Mice
• Share to Mutation